EDAP TMS EDAP 深 沪
等待开盘 10-20 09:30:00 美东时间
2.24
-0.180
-7.44%
华盛通- 最 高2.3825
- 今 开2.25
- 成交量 2.23万股
- 最 低 2.14
- 昨 收 2.42
- 总市值 8375.83万
- 52周最高 3.08
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 1.21
- 委 比 -17.99%
- 总股本 3739.21万
- 历史最高 12.65
- 量 比 0.17
- 振 幅 10.02%
- 历史最低 1.15
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
EDAP TMS SA, a global leader in robotic energy-based therapies, highlighted its non-invasive Focal One Robotic HIFU treatment during Prostate Cancer Awareness Month. The therapy was featured on *Health Uncensored with Dr. Drew* on the Lifetime Network, reaching millions nationwide. Patient Peter D. shared his positive experience, emphasizing minimal disruption to daily life. His urologist, Dr. Eric Giesler, noted Focal One's ability to target pro...
09-30 11:00
Focal One® HIFU Receives Prestigious Innovation Award
EDAP TMS SA, a global leader in robotic energy-based therapies, has received the 2025 Endourological Society Industry Award for Innovations in Endourological Instrumentation for its Focal One HIFU platform. The award recognizes Focal One as the first focal therapy technology to achieve this distinction, acknowledging its pioneering role in advancing robotic HIFU treatments for prostate cancer. CEO Ryan Rhodes highlighted the company's commitment ...
09-16 11:00
EDAP TMS Secures HIFU Reimbursement for Prostate Cancer in France
EDAP TMS ( ($EDAP) ) has issued an update. On September 8, 2025, EDAP TMS annou...
09-08 19:27
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
EDAP TMS S.A. reports Q2 results
EDAP TMS S.A. press release (NASDAQ:EDAP): Q2 net loss of $6.4M Revenue of $18.4M (+8.2% Y/Y). More on EDAP TMS S.A. EDAP executes letter of intent for €36M financing from European Investment Bank See...
08-28 19:09
Earnings Scheduled For August 28, 2025
Companies Reporting Before The Bell • Li Auto (NASDAQ:LI) is expected to report...
08-28 16:32
What's Next: Edap TMS's Earnings Preview
Edap TMS (NASDAQ:EDAP) is gearing up to announce its quarterly earnings on Thur...
08-28 00:03
EDAP executes letter of intent for €36M financing from European Investment Bank
Robotic energy-based therapies company EDAP TMS (NASDAQ:EDAP) announced on Tuesday the execution of a letter of intent for a €36M credit facility with the European Investment Bank. Proceeds will be us...
08-26 19:38
EDAP Announces Letter of Intent for 36 Million Euro Credit Facility to Accelerate Growth and Strategic Expansion
EDAP TMS SA has secured a €36 million credit facility with the European Investment Bank to expand its Focal One® Robotic HIFU technology for prostate cancer treatment. CEO Ryan Rhodes highlighted the significance of this low-interest funding, which will also support developing new clinical applications. EDAP is a leader in robotic energy-based therapies, offering minimally invasive solutions for various conditions.
08-26 11:00
